SAN DIEGO , Nov. 20, 2020 /PRNewswire/ -- Biocept, Inc . (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic assays, products and services designed to provide physicians with clinically actionable information to improve patient outcomes, announces the results of a study analyzing
SAN DIEGO , Oct. 5, 2020 /PRNewswire/ -- Biocept, Inc . (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic tests and services for physicians treating cancer patients , announces results from a prospective study comparing its Target Selector™ cerebrospinal fluid testing to
Abstract published in the Journal of Molecular Diagnostics shows 200-1,000 times increase in assay sensitivity with the addition of Switch-Blocker technology SAN DIEGO --(BUSINESS WIRE)--Nov. 9, 2021-- Biocept, Inc . (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and
Data to be presented at Molecular Med Tri-Con Virtual Conference SAN DIEGO --(BUSINESS WIRE)--Feb. 16, 2021-- Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, will present data showing that its Target Selector™ molecular assay kit detects
Large prospective multi-center clinical trial designed to evaluate the impact of cancer biomarker detection and serial monitoring using liquid biopsy to improve the outcomes of patients with lung cancerPatient-founded research consortium of 25 global oncology centers to create large, well-annotated, uniformly collected biorepository of lung cancer patient blood samples
Biocept's patented collection tubes now available from VWR for the safe transport of patient specimens containing both circulating cell-free DNA (cfDNA) and circulating tumor cells (CTCs) at room temperature SAN DIEGO , June 11, 2018 /PRNewswire/ -- Biocept, Inc .
